A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC731636, IND) in Children With CD30+ Recurrent Anaplastic Large Cell Lymphoma.

Trial Profile

A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC731636, IND) in Children With CD30+ Recurrent Anaplastic Large Cell Lymphoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs SGN 30 (Primary) ; Carboplatin; Etoposide; Ifosfamide
  • Indications Anaplastic large cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top